Denis Du Bois

Denis Du Bois is CEO of P5 Group, a cleantech marketing firm, and founding editor of Energy Priorities Magazine. He will moderate the MIT Enterprise Forum "Tech to Grid: How Technology Entrepreneurs Can Find Opportunities in the Smart Grid Revolution" in Bellevue November 10.

Recent posts

How the Smart Grid Opportunity Looks a Lot Like the Internet Once Did
The smart grid is a new technology arena that will change how Americans think about electricity. Entrepreneurs jumping into this sector give many reasons — to save the planet, save lives,... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

From Our Editors · Podcast
Xcelerating Life Sciences San Diego: The Highlights Podcast
Learn what's fueling San Diego's biotech investment and partnership opportunities

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

BioNTech's mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data

CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy

On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO

Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug

Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs

Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

Akili Interactive’s Video Game for ADHD Gets the FDA All Clear

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The 2020 National Xconomy Awards

Xcelerating Life Sciences Seattle

Xcelerating Life Sciences New York

Denis Du Bois

Recent posts

How the Smart Grid Opportunity Looks a Lot Like the Internet Once Did

Underwriters and Partners

The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace

What’s Next in Neuroscience Therapies

Xcelerating Life Sciences San Diego: The Highlights Podcast

Xconomy on Demand

We offer a number of ways to subscribe for free!